Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
The attrition rate of drugs in clinical trials is generally quite high, with estimates suggesting that approximately 90% of drugs fail to make it through the process. The identification of unexpected toxicity issues during preclinical stages is a significant factor contributing to this high rate of failure. These issues can have a major impact on the success of a drug and must be carefully considered throughout the development process. These late-stage rejections or withdrawals of drug candidates significantly increase the costs associated with drug development, particularly when toxicity is detected during clinical trials or after market release. Understanding drug-biological target interactions is essential for evaluating compound toxicity and safety, as well as predicting therapeutic effects and potential off-target effects that could lead to toxicity. This will enable scientists to predict and assess the safety profiles of drug candidates more accurately. Evaluation of toxicity and safety is a critical aspect of drug development, and biomolecules, particularly proteins, play vital roles in complex biological networks and often serve as targets for various chemicals. Therefore, a better understanding of these interactions is crucial for the advancement of drug development. The development of computational methods for evaluating protein-ligand interactions and predicting toxicity is emerging as a promising approach that adheres to the 3Rs principles (replace, reduce, and refine) and has garnered significant attention in recent years. In this review, we present a thorough examination of the latest breakthroughs in drug toxicity prediction, highlighting the significance of drug-target binding affinity in anticipating and mitigating possible adverse effects. In doing so, we aim to contribute to the development of more effective and secure drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Amorim et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
XGBoost: A Scalable Tree Boosting System
Chen, T., & Guestrin, C. (2016) · Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining · doi:10.1145/2939672.2939785 · Cited by 54,569 · cited 1×
“Using an ensemble approach that leverages DNN, RF, and extreme Gradient Boosting (XGBoost), 62 they also examined the contribution of each input fingerprint to the prediction output, thus gaining insight into warning substructures that might be indicative of the cardiotoxicity of the input compound.”
MethodDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
PubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac956 · Cited by 3,443
Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab255 · Cited by 2,857
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322
SchNet – A deep learning architecture for molecules and materials
Schütt, K. T., Sauceda, H. E., Kindermans, P.-J., Tkatchenko, A., & Müller, K.-R. (2018) · The Journal of Chemical Physics · doi:10.1063/1.5019779 · Cited by 2,217
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
Research works printed but not linked: 1
- Feng Q.; Dueva E.; Cherkasov A.; Ester M. PADME: A Deep Learning-Based Framework for Drug-Target Interaction Prediction. arXiv [cs.LG], 2018.
Cited by
Items 101–149 of 149
Development of parasitic disease biobank and new antileishmanial agents
Kumar, A. (2026) · Journal of Parasitic Diseases · doi:10.1007/s12639-025-01898-w
“No idea related to drug delivery issues, i.e., absorption problem, elimination of the drug (individual variations), interference of host-related factors, host immunity, etc., are associated with in vitro studies (Amorim et al. 2024).”
Leveraging AI and Big Data for Drug Development: Transforming Pharmaceutical R&D
Javkar, S., Pawar, M. K., Salati, A., Priya, L., Pasha, M. Y., & Yogapriya, J. (2025) · International Conference for Advancement in Technology (ICONAT) · doi:10.1109/iconat66879.2025.11362534
“One major shortcoming is that the generalization and reproducibility of AI models over different datasets are needed, specifically when predicting ADME/Tox properties (Huang et al., 2021) and toxicity predictions (Amorim et al., 2024).”
Asano, H., Tian, Y., Hatabu, A., Fukuzawa, K., Takaya, D., & Ikeda, K. (2026) · Research Square · doi:10.21203/rs.3.rs-8923363/v1
Kushwah, R., Kumari, M., & Garg, P. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2026.2643911
“The detection and risk assessment of nitrosamines requires both empirical measurement and predictive modeling (Amorim et al. 2024; Ashworth et al. 2023), as each approach offers complementary strengths (Figure 8).”
Halma, M., Marik, P. E., Varón, J., & Tuszyński, J. A. (2026) · Annals of Research in Oncology · doi:10.48286/aro.2026.122
Santos, L. L., Brandão, L. B., Rodrigues, A. B. L., Martins, R. L., da Costa, A. L. P., Faustino, C. G., de Medeiros, F. A., & de Almeida, S. S. M. D. S. (2026) · ACS Omega · doi:10.1021/acsomega.6c00802
Efendi, M. R. (. )., Rintjap, D. (. S., Sulasmi, S. (., Rokot, A. (., Faisal, H. (., Jannah, S. N. (., Doloking, H. (., Astryna, S. Y. (., Safrina, S. (., Pratama, A. A. (., et al. (2026) · Neliti
Evaluation of acute and subacute toxicity of Argyreia acuta Lour. leaf extract in mice
Nhung, T. T. P., & Quoc, L. P. T. (2026) · International Journal of Agricultural Technology · doi:10.63369/ijat.2026.22.1.287-306
“Toxicity assessment, therefore, remains a key step for defining safe exposure ranges and supporting responsible development of plant-derived products (Amorim et al ., 2024).”
Lazinski, L. M. (2024) · theses.fr (ABES) · doi:10.70675/6c465b6bzea1cz43d3z9a97z5817fc386099
Gao, L., He, W., Gao, J., He, J., Wang, X., & Huang, S. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005215
Islam, M. M., Kasana, S., Kurmi, B. D., Gupta, G. D., Eyüpoğlu, V., Priya, S., Rawat, R., & Patel, P. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00683-9
Kumar, R., Upendra, Tripathi, R., & Sahu, T. P. (2026) · International Conference on Computing, Electronics & Communications Engineering (iCCECE) · doi:10.1109/iccece69715.2026.11493092
“With attrition rates exceeding 90% from preclinical stages through regulatory approval, the pharmaceutical industry faces significant obstacles in drug development [1].”
Rehman, M. U. (2026) · Research Square · doi:10.21203/rs.3.rs-9615735/v1
Jibrin, A., Uzairu, A., Shallangwa, G. A., Abechi, S. E., & Umar, A. B. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100404
Khanam, T., Yeasmin, L., & Akter, M. F. (2026) · Integrative Biomedical Research · doi:10.25163/biomedical.10110733
Ramanathan, S., Brindha, K., Vijayalakshmi, P., Viknesh, K., Likson, A., Desai, D., & Selvaraj, C. (2026) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2026.04.001
Sardana, A., & Goyal, L. M. (2026) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-026-07802-6
Pazoki, H., Haghparast-Kenari, B., Niyyati, M., Ghasemi, A., & Kalankesh, L. R. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108584
Zhang, D., Zhang, L., Zhang, L., Jia, H., Zhao, X., Ren, S., Wu, Y., Zhu, Y., & Zhang, X. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11602-6
Patel, N., Gupta, A., Mishra, R., Pandey, S. N., Goyal, K., Ali, H., Maji, C., Rekha, A., Hussain, M. S., Singh, S. K., et al. (2026) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2026.2680653
Toxicology and Therapeutics: The Fine Line between Poisons and Medicines
Shaker, T. (2026) · Kerbala Journal of Veterinary Medical Sciences · doi:10.65639/kjvm.2026.183
“Precise microphysiological in vitro models and models of human relevance have thus been created to enhance the forecasting of substance reaction and decrease the disparity amid preclinical toxicity indicators and clinical results (8).”
Mai, N. P., Quan, N. Y., Duc, N. D., & Xuan, T. D. (2026) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.70795
“44 Moreover, investigations at multiple levels, including cellular studies, in vivo experiments and preclinical assessments, are also necessary.”
A computational drug design approach for optimization of PHGDH inhibitors in cancer metabolism
Pal, K., Islam, M. M., Kurmi, B. D., Rawat, R., Eyüpoğlu, V., & Patel, P. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100460
Izadiyan, Z., Ali, R. R., Webster, T. J., Esfahan, Z. M., & Shameli, K. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100478
Wiśniewski, K., Nowak, M., & Adamczyk, T. (2025) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/lx1ewvcmku
Kumar, S. (2025) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000451
The role of generative artificial intelligence in personalized drug development and safety
Ilyas, H., & Mohid, S. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43934-6.00027-4
Saristiana, Y., Laili, N. F., Prasetyawan, F., Probosiwi, N., Ilmi, T., & Salmasfattah, N. (2026) · Journal of Marine Pharmacy and Biomedicine · doi:10.64595/jmpb.122026.734
Saristiana, Y., Prasetyawan, F., Mildawati, R., Ariawan, M. W., Astutik, W., & Indrayanti, D. (2026) · Journal of Marine Pharmacy and Biomedicine · doi:10.64595/jmpb.122026.730
“Evaluasi keamanan obat menjadi salah satu tahapan yang sangat penting dalam proses pengembangan maupun penggunaan obat di Masyarakat [9].”
Analisis Prediksi Komputasi Toxicity Targets dan Toxicity Metabolism dari Obat Piroksikam
Prasetyawan, F., Ariawan, M. W., Saristiana, Y., & Mildawati, R. (2026) · Journal of Marine Pharmacy and Biomedicine · doi:10.64595/jmpb.122026.736
Prasetyawan, F., Saristiana, Y., Ariawan, M. W., Arifin, C., Rofiq, A., Herman, H., & Dhafin, A. A. (2026) · Journal of Marine Pharmacy and Biomedicine · doi:10.64595/jmpb.122026.735
“Keamanan obat tidak hanya ditentukan oleh efektivitas terapeutiknya, tetapi juga oleh kemungkinan munculnya efek toksik yang dapat memengaruhi berbagai organ maupun sistem biologis [6].”
Prasetyawan, F., Saristiana, Y., Ariawan, M. W., Ilmi, T., & Lestari, S. (2026) · Journal of Marine Pharmacy and Biomedicine · doi:10.64595/jmpb.122026.737
Deep metadata annotations and FAIR enhancement of DrugMatrix in vitro bioassay data
Ross, N. C., Jagodnik, K. M., Oprea, T. I., & Schürer, S. C. (2026) · Scientific Data · doi:10.1038/s41597-026-07570-z
Deng, G., Jiang, G., Liu, B., Zuo, S., Zhang, X., & Yuan, L. (2026) · Science China Materials · doi:10.1007/s40843-026-4228-y
Toxicity and Safety Assessment of Heterocyclic Anticancer Agents
Kesharwani, G., Mishra, A., Mishra, P., & Dewangan, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898817084126010012
Cao, P., Liu, J., Zhu, L., Jiang, X., & Wei, Y. (2026) · International Conference on Bioinformatics and Intelligent Computing (BIC) · doi:10.1145/3809986.3810043
Gubitosa, J., Rizzi, V., Fini, P., & Cosma, P. (2026) · Progress in Materials Science · doi:10.1016/j.pmatsci.2026.101820
Integrating structural and omics data for drug discovery
Neha, & Raza, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44988-8.00003-4
Ensemble-Based Machine Learning for Drug-Induced Autoimmunity Prediction Using Molecular Descriptors
Fouda, M. I., Sabor, A., & Mohammed, A. (2026) · Intelligent Methods, Systems, and Applications (IMSA) · doi:10.1109/imsa70415.2026.11700376
“The broader computational toxicology literature supports machine learning for early drug-safety assessment, while showing that performance depends on data size, representation, and endpoint definition [2], [3].”
Rokade, A. K., & Nguyen, H. T. A. (2026) · Vietnam Journal of Biotechnology · doi:10.15625/vjbt-24869
Susilawati, A., Maharani, S. A., & Oktaviani, D. T. (2026) · Jurnal Mandala Pharmacon Indonesia · doi:10.35311/jmpi.v12i1.1234
“…contains various bioactive secondary metabolites, particularly curcuminoids and sesquiterpenes such as xanthorrhizol, which have been reported to possess antioxidant, anti-inflammatory, and antihyperglycemic activities in several experimental studies (Amorim et al. , 2024; Simamora et al. , 2024).”
Kalaimathi, K., Tamilselvan, S., Nikpassand, M., Manikandan, P., Kaleeswaran, S., Vimalan, M., & Saral, A. K. A. (2026) · Asian Journal of Chemistry · doi:10.14233/ajchem.2026.36595
Drug-Likeness, Druggability, and Molecular Developability via Chemometric Evaluation: A Review
Yu, B., Zhu, H.-Y., Gu, R., Du, S., Shi, W., & Xu, L. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c02860
Current applications of isothermal titration calorimetry for lead optimization
Hu, H., Guerrero, M., & Bao, Y. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2746971
Bella-Omunagbe, M., Adebayo, A. H., & Chinedu, S. N. (2026) · Bioinformatics and Biology Insights · doi:10.1177/11779322261468102
Application of integrative metabonomics in preclinical toxicology to augment drug development
Kadyrov, J. (2026) · Murdoch University Research Portal · doi:10.60867/00000190
Dudwadkar, K., & Khan, S. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106289
Alshehri, M. M., Ali, N., Alharbi, M., Alasmari, F. F., Alanazi, A., Rehman, M. T., Umar, H. I., Omowunmi, D. M., Alshammari, A., Nishat, S., et al. (2026) · Journal of King Saud University - Science · doi:10.25259/jksus_425_2026
Metadata
- Authors
- Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S.
- Affiliations
- Centro de Neurociências e Biologia Celular (PT)
- CNC-UC─Center for Neuroscience and Cell Biology, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
- Corresponding author
- Moreira, Irina S.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-05-17
- Volume
- 37
- Issue
- 6
- Pages
- 827-849
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- PMC
- PMC11187637
- OpenAlex
- W4397001794
- Cited by
- 132
- References
- 140
- Citations by year
- 2026: 69 · 2025: 56 · 2024: 7
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Chemical Research in Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Regional Development Fund
- Funda??o para a Ci?ncia e a Tecnologia (DSAIPA/DS/0118/2020, LA/P/0058/2020, SFRH/BD/144966/2019, UIDB/04539/2020, UIDP/04539/2020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- drug toxicity prediction, drug safety, drug development attrition, protein-ligand interactions, drug binding affinity, off-target effects, computational toxicology, 3Rs, preclinical toxicity testing
- MeSH terms
- Drug Development, Animals, Humans, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.